WuXi AppTec, a leading global provider of R&D and manufacturing services for the pharmaceutical and life sciences industry, has released its financial results for the first quarter ending March 31, 2024. Here’s a breakdown of the key highlights from the…
Amgen (NASDAQ:AMGN) today announced that it will report its first quarter 2024 financial results on Thursday, May 2, 2024, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET. Participating…
Vertex Pharmaceuticals (Nasdaq: VRTX) has received approval from the European Commission for the expansion of KALYDECO® (ivacaftor) labeling. This approval allows for the treatment of infants as young as 1 month old with cystic fibrosis (CF) who possess specific mutations…
Today, Pfizer Inc. (NYSE: PFE) announced the approval of BEQVEZ™ (fidanacogene elaparvovec-dzkt) by the U.S. Food and Drug Administration (FDA) for the treatment of adults grappling with moderate to severe hemophilia B. This approval is particularly significant for individuals currently…
Moderna, Inc. (NASDAQ: MRNA) and OpenAI have announced a collaborative effort aimed at harnessing the potential of artificial intelligence (AI) to revolutionize both business and healthcare. Moderna, known for its digital-first approach and early adoption of machine learning, is poised…
Lupin, a global pharmaceutical giant, proudly announces the reception of the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its manufacturing facility in Aurangabad. Conducted from March 6 to March 15, 2024, the…
Moderna, Inc. (NASDAQ: MRNA) has announced a significant milestone in its global efforts to combat COVID-19 by securing a contract with Brazil’s Ministry of Health (Ministério da Saúde). The contract entails supplying Moderna’s mRNA COVID-19 vaccine as a crucial component…
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) has unveiled significant progress in its suzetrigine pain program, potentially introducing the first new class of medication for acute and neuropathic pain in over twenty years. Suzetrigine, an oral selective NaV1.8 pain signal inhibitor (previously…
Novartis has revealed findings from the ALITHIOS open-label extension study, demonstrating the sustained efficacy of continuous Kesimpta® (ofatumumab) treatment for up to six years in individuals recently diagnosed with relapsing multiple sclerosis (RMS). These individuals, termed “treatment-naïve,” initiated treatment within…
Today marked a significant milestone in healthcare as the World Health Organization (WHO) unveiled the Patient Safety Rights Charter during the Global Ministerial Summit on Patient Safety. This groundbreaking Charter, the first of its kind, delineates patients’ rights within the…
Merck’s Curiosity Cube Hits the Road: Inspiring 45,000 Students Across 14 Countries Merck, a global leader in science and technology, has launched its 2024 Curiosity Cube tour from Darmstadt, Germany, marking the beginning of a journey to engage and educate…
Modalis Therapeutics Corporation (Modalis) (Tokyo Stock Exchange: 4883) announced that it has entered into an agreement with Ginkgo Bioworks (Ginkgo) to join the Ginkgo Technology Network. This strategic alliance will enable Ginkgo’s global customers in the cell and gene therapy fields…